

**TIANJIN PHARMACEUTICAL (SINGAPORE)  
INTERNATIONAL INVESTMENT PTE. LTD.**

(Company Registration Number: 200922469M)

(Incorporated in the Republic of Singapore)

**NOTICE TO SHAREHOLDERS REGARDING  
ELECTRONIC DESPATCH OF OFFER DOCUMENT**

26 March 2021

To : The holders of S Offer Shares

Dear Sir/Madam

**MANDATORY CONDITIONAL CASH OFFER (THE “S SHARES CHAIN OFFER”) BY DBS BANK LTD. AND BANK OF CHINA LIMITED, SINGAPORE BRANCH FOR AND ON BEHALF OF TIANJIN PHARMACEUTICAL (SINGAPORE) INTERNATIONAL INVESTMENT PTE. LTD. (THE “OFFEROR”) FOR ALL THE ORDINARY SHARES OF TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED (THE “COMPANY”) WHICH ARE LISTED ON THE OFFICIAL LIST OF THE SINGAPORE EXCHANGE SECURITIES TRADING LIMITED, OTHER THAN THOSE ALREADY OWNED, CONTROLLED OR AGREED TO BE ACQUIRED BY JINHUSHEN BIOLOGICAL MEDICAL SCIENCE AND TECHNOLOGY CO., LTD (津沪深生物医药科技有限公司) (THE “PURCHASER”), THE OFFEROR AND TIANJIN PHARMACEUTICAL HOLDINGS CO., LTD. (天津市医药集团有限公司) (“TPH”) (THE “S OFFER SHARES”)**

**1. INTRODUCTION**

The board of directors (the “**Board**”) of the Offeror refers to the announcement released on 26 March 2021 by DBS Bank Ltd. and Bank of China Limited, Singapore Branch, for and on behalf of the Offeror, regarding the despatch of the formal offer document dated 26 March 2021 (the “**Offer Document**”) containing, *inter alia*, the terms and conditions of the S Shares Chain Offer.

**2. ELECTRONIC DESPATCH OF OFFER DOCUMENT**

The Board wishes to inform the holders of S Offer Shares that in connection with the S Shares Chain Offer, the Offeror has opted to electronically despatch the Offer Document, pursuant to the Securities Industry Council’s Public Statement on Despatch of Take-over Documents under the Singapore Code on Take-overs and Mergers (the “**Code**”) issued on 6 May 2020 and Public Statement on the Extension of the Temporary Measures to Allow for Electronic Despatch of Take-over Documents under the Code issued on 29 September 2020.

Accordingly, an electronic copy of the Offer Document dated 26 March 2021 and the Form of Acceptance and Authorisation for S Offer Shares (the “**FAA**”) have, as of the date of this Notice, been published on the website of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”). To access the electronic version of the Offer Document and the FAA:

- (a) you may directly access the Company’s announcement page on the website of the SGX-ST by scanning the following QR code:



- (b) you may also access the website of the SGX-ST at <https://www.sgx.com> and select the section “**Securities**”, select “**Company Information**” and then “**Company Announcements**” from the drop-down menu list and type the name of the Company: “**Tianjin Zhong Xin Pharm Group**” in the box titled “**Filter by Company/Security Name**”. “**Tianjin Zhong Xin Pharm Group**” will appear as a drop-down item below the filter box.

Thereafter, please select the announcement dated 26 March 2021 titled “Formal Offer Announcement and Electronic Despatch of Offer Document”. The Offer Document and the FAA can be accessed by clicking on the links under the section titled “**Attachments**” at the bottom of the announcement.

The electronic version of the Offer Document and the FAA may also be accessed directly on the “**公司动态(NEWS)**” page on the website of the Company at the following URL: <http://www.zhongxinp.com/>. Alternatively, you may access the page by scanning the following QR code:



A copy of the FAA is also enclosed with this Notice.

### **3. RESPONSIBILITY STATEMENT**

The directors of the Offeror and TPH (including those who may have delegated detailed supervision of this Notice) have taken all reasonable care to ensure that the facts stated and opinions expressed in this Notice (other than those relating to the Company) are fair and accurate and that there are no other material facts not contained in this Notice, the omission of which would make any statement in this Notice misleading.

Where any information has been extracted or reproduced from published or otherwise publicly available sources or obtained from the Company, the sole responsibility of the directors of the Offeror and TPH has been to ensure through reasonable enquiries that such information is accurately extracted from such sources or, as the case may be, reflected or reproduced in this Notice.

The directors of the Offeror and TPH jointly and severally accept responsibility accordingly.

BY ORDER OF THE BOARD

**TIANJIN PHARMACEUTICAL (SINGAPORE) INTERNATIONAL INVESTMENT PTE. LTD.**

26 March 2021